Radiometal complexes in molecular imaging and therapy

Current Medicinal Chemistry

Volumn 17, Issue 31, 2010, Pages 3673-3683

  Rey, A M ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

Diagnosis; Metals; Nuclear medicine; Radionuclides; Radiopharmaceuticals; Radiotherapy

Indexed keywords

GALLIUM 68; LIGAND; LUTETIUM 177; METAL COMPLEX; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SAMARIUM 153; TECHNETIUM 99M;

ARTICLE; DRUG RECEPTOR BINDING; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR THERAPY; TECHNIQUE;

CHELATING AGENTS; COORDINATION COMPLEXES; HALF-LIFE; HUMANS; METALS; MOLECULAR IMAGING; RADIOACTIVITY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 78449250994     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793213733     Document Type: Article

References (110)

1. Reichert, D.E.; Lewis, J. S.; Anderson, C.J. Metal complexes as diagnostic tools. Coord. Chem. Rev., 1999, 184, 3-66.
2. Jurisson, S.; Lydon, J.D. Potential Technetium Small Molecule Radiopharmaceuticals. Chem. Rev., 1999, 99, 2205-2218.
3. Liu, S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem. Soc. Rev., 2004, 33, 445-461.
4. 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl. Med. Biol., 2005, 32, 1-20.
5. Volkert, W.A.; Hoffman, T.J. Therapeutic radiopharmaceuticals. Chem. Rev., 1999, 99, 2269-2292.
6. Neves, M.; Kling, A.; Oliveira, A. Radionuclides used for therapy and suggestion for new candidates. J. Radioanal. Nucl. Chem., 2005, 266(3), 377-384.
7. 177Lu with zoledronic acid for bone pain therapy. Appl. Radiat. Isot., 2009, 67, 11-13.
8. Jurisson, S; Cutler, C.; Smith S.V. Radiometal complexes: characterization and relevant in vitro studies. Q. J. Nucl. Med. Mol. Imaging, 2008, 52, 222-234.
9. Liu, S.; Edwards, D.S. Fundamental of receptor-based diagnostic metalloradiopharmaceuticals. Top. Curr. Chem., 2002, 222, 259-279.
10. Heeg, M.J.; Jurisson, S.S. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc. Chem. Res., 1999, 32, 1053-1060.
11. Segrè, E.; Seaborg, G.T. Nuclear Isomerism in Element 43. Phys. Rev., 1938, 54, 772-772.
12. Richards, P.; Nuclide generators. In: Radioactive Pharmaceuticals Symp. N° 6. Conf. 55. US Atomic Energy Commission, Oak Ridge, 1966.
13. Jurisson, S.; Berning, D.; Jia, W.; Ma, D. Coordination Compounds in Nuclear Medicine. Chem. Rev., 1993, 93, 1137-1156.
14. 111In. J. Nucl. Med., 1979, 20, 1273-1278.
15. Subramanian, G.; J.G. McAfee; Blair, R.J. Technetium-99mMethylene BiphosphonateA Superior Agent for Skeletal Imaging: Comparison with other Technetium Complexes. J. Nucl. Med., 1975, 16, 744-755.
16. Pinkerton, T.C.; Heineman, W. R.; Deutsch, E. Separation of technetium hydroxyethylidene biphosphonate complexes by anionexchange high performance liquid chromatography. Anal. Chem., 1980, 52, 1106-1110.
17. Wilson, G.M.; Pinkerton, T.C. Determination of charge and size of technetium biphosphonate complexes by anion-exchange liquid chromatography. Anal. Chem., 1985, 57, 246-253.
18. Libson, K.; Deutsch, E.; Barnett, B.L. Structural characterization of a technetium-99-biphosphonate complex. Implications for the chemistry of technetium-99m skeletal imaging agents. J. Am. Chem. Soc., 1980, 102, 2476-2478.
19. Francis, M.D.; Fergusson, D.L.; Tofe, A.J.; Bevan, J.A.; Michaels, S.E. Comparative evaluation of three biphosphonates: in vitro adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). J. Nucl. Med., 1980, 21, 1185-1189.
20. Vallabhajosula, S.; Zimmerman, R.E.; Picard, M.; Stritzke, P; Mena, I.; Hellman, R.S.; Tikofsky, R.S.; Stabin, M.G.; Morgan, R.A.; Goldsmith, S.J. Technetium-99m ECD: A new brain imaging agent: In vivo kinetics and biodistribution studies in normal human subjects. J. Nucl. Med., 1989, 30, 599-604.
21. 99mTc-bicisate (99mTc-ECD). J. Cereb. Blood Flow Metab., 1994, 14, Suppl. 1, 4-11.
22. Jones, A.G.; Abrams, M.J.; Davison, A.; Brodack, J.W.; Toothaker, A.K.; Adelstein, S.J.; Kassis, A. Biological studies of a new class of technetium complexes: the hexakis(alkylisonitrile)technetium(I) cations. Int. J. Nucl. Med. Biol., 1984, 11, 225-234.
23. Carvalho, P.A.; Chiu, M.L.; Kronauge, J.F.; Kawamura, M.; Jones, A.G., Holman, B.L.; Piwnica-Worms, D. Subcellular distribution and analysis of Technetium-99m-MIBI in isolated perfused rat hearts. J. Nucl. Med., 1992, 33, 1516-1522.
24. Kung, M.; Stevenson, D.A., Plössl, K.; Meegalla, S.K.; Beckwith, A.; Essam, W.D.; Mu, M.; Lucki, I.; Kung, H.F. [99mTc] TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur. J. Nucl. Med., 1997, 24, 372-380.
25. Dresel, S.; Kung, M.; Plössl, K.; Meegalla, S.; Kung, H. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur. J. Nucl. Med., 1998, 25, 31-39.
26. 99mTc]TRODAT-1 to Dopamine Transporters in Patients with Parkinson's Disease and in Healthy Volunteers. J. Nucl. Med., 2000, 41, 584-589.
27. Felicio, AC.; Godeiro-Junior, C.; Shih, MC.; Borges, V.; Silva, SM.; de Aguiar, P.C.; Hoexter, MQ.; Barsottini, OG.; Andrade, LA.; Bressan, RA.; Ferraz, HB. Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. J. Neurol. Sci., 2010, 15, 64-68.
28. Felicio, AC.; Godeiro-Junior, C.; Moriyama, TS.; Shih, MC.; Hoexter, MQ.; Borges, V.; Silva, SM.; Aguiar, P de C.; Andrade, LA.; Bressan, RA.; Ferraz, HB. Degenerative parkinsonism in patients with psychogenic parkinsonism: A dopamine transporter imaging study. Clin. Neurol. Neurosurg. 2010, 112(4), 282-285.
29. Thakur, M.L.; DeFulvio, J.; Richard, M.D.; Park, C.H. Technetium-99m labeled monoclonal antibodies: evaluation of reducing agents. Nucl. Med. Biol., 1991, 18, 227-233.
30. 99mTc. Nucl. Med. Biol., 1989, 16, 171-176.
31. Baulieu, F.; Bourlier, P.; Scotto, B.; Mor, C.; Eder, V.; Picon, L.; De Calan, L.; Dorval, E.; Pottier, J.M.; Baulieu, J.M. The value of inmunoscintigraphy in the detection of recurrent colorectal cancer. Nucl. Med. Commun., 2001, 22, 1295-1304.
32. Moffat, F.; Pinsky, C.; Hammershaimb, L.; Petrelli N.J.; Patt Y.Z.; Whaley F.S.; Goldenberg D.M. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J. Clin. Oncol., 1996, 14, 2295-2305.
33. Banerjee, S.; Raghavan, M.; Pillai A.; Ramamoorthy, N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin. Nucl. Med., 2001, 31, 260-277.
34. 99mTc-protein conjugates. Bioconj. Chem., 1991, 2, 333-336.
35. Abrams, M.J.; Juweid, M.; Ten Kate, C.I.; Schwartz, D.A.; Hauser, M.M.; Gaul, F.E.; Fuccello, A.J.; Rubin, R.H.; Strauss, H.W.; Fischman, A.J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med., 1990, 31, 2022-2028.
36. 99m-Technetium-labeled peptideHYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl. Med. Biol., 1999, 26, 389-396.
37. 99mTc]chelator-peptide conjugates. Bioconj. Chem., 1996, 7, 196-202.
38. 99mTc. Bioconj. Chem., 1997, 8, 146-154.
39. 99mTc-labeling of highly potent small peptides. Bioconj. Chem., 1997, 8, 621-636.
40. 99mTc-Labeling of Small Biomolecules. Bioconj. Chem., 2003, 14, 720-727.
41. + (M=Re, Tc) directed towards radiopharmaceutical application. Coord. Chem. Rev., 1999, 190, 901-919.
42. 99mTcO4]in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc., 1998, 120, 7987-7988.
43. Alberto R. Advances and perspectives of aqueous organometallic rhenium and technetium chemistry. In: Technetium, rhenium and other metals in chemistry and nuclear medicine SG, Editoriali; Padova, 2002, Vol. 6, pp. 3-21.
44. Baldas, J.; Bonnyman, J. Substitution reactions of 99mTcNCl-4--A route to a new class of 99mTc-radiopharmaceuticals. Int. J. Appl. Radiat. Isot., 1985, 36, 133-139.
45. Tisato, F.; Refosco, F.; Porchia, M.; Bolzati, C.; Bandoli, G.; Dolmella, A.; Duatti, A.; Boschi, A.; Jung, C.M.; Pietzsch, H.J.; Kraus, W. The crucial role of the diphosphine heteroatom X in the stereochemistry and stabilization of the substitution-inert [M(N)(PXP)]2+ metal fragments (M = Tc, Re; PXP = diphosphine ligand). Inorg. Chem., 2004, 43, 8617-8625.
46. 2+ (PXP = diphosphine ligand). A novel tool for the selective labeling of small molecules. J. Am. Chem. Soc., 2002, 124, 11468-11479.
47. Spies, H.; Glaser, M.; Pietzsch, H.J.; Hahn, F.E.; Lügger, T. Synthesis and reactions of trigonal-bipyramidal rhenium and technetium complexes with a tripodal, tetradentate NS3 ligand. Inorg. Chim. Acta, 1995, 240, 465-478.
48. Pietzsch, H.J.; Gupta, A.; Syhre, R.; Leibnitz, P.; Spies, S. Mixedligand Technetium(III) complexes with tetradendate/monodendate NS3/isocyanide coordination: A new nonpolar technetium chelate system for the design of neutral and lipophilic complexes stable in vivo. Bioconj. Chem., 2001, 12, 538-544.
49. 99mTc-labelled RGD-Peptides using the 4+1 mixed-ligand approach. In: Technetium, rhenium and other metals in chemistry and Nuclear Medicine. SG, Editorial; Padova, 2006, Vol.7, pp. 331-331.
50. Decristoforo, C.; Santos, I.; Pietzsch, H.J.; Kuenstler, J.U.; Duatti, A.; Smith, C.J.; Rey, A.; Alberto, R.; Von Guggenberg, E.; Haubner, R. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores. Q. J. Nucl. Med. Mol. Imaging, 2007, 51, 33-41.
51. Labeling of small biomolecules using novel Technetium-99m cores. IAEA Technical Report Series 458, IAEA, Vienna, 2007. (http://www-pub.iaea.org/MTCD/publications/PDF/trs459_web.pdf).
52. Mindt, T.L.; Struthers, H.; Brans, L.; Anguelov, T.; Schweinsberg, C.; Maes, V.; Tourwe, D.; Schibli, R. "Click to Chelate": Synthesis and installation of metal chelates into biomolecules in a single step. J. Am. Chem. Soc., 2006, 128, 15096-15097.
53. Mamat, C.; Ramenda, T.; Wuest, FR. Recent applications of click chemistry for the synthesis of radiotracers for molecular imaging. Mini-Rev. Org. Chem., 2009, 6, 21-34.
54. Nwe, K.; Brechbiel, MW. Growing applications of click chemistry for bioconjugation in contemporary biomedical research. Cancer Biother. Radiopharm., 2009, 24(3), 289-302.
55. Weiner, R.E.; Thakur, M.L. Radiolabeled, peptides in oncology: role in diagnosis and treatment. Bio Drugs, 2005, 19, 145-163.
56. Virgolini, I.; Traub, T.; Novotny, C.; Leimer, M.; Füger, B.; Li, S.R.; Patri, P.; Pangerl, T.; Angelberger, P.; Raderer, M.; Andreae, F.; Kurtaran, A.; Dudczak, R. New trends in peptide receptor radioligands. Q. J. Nucl. Med., 2001, 45, 153-159.
57. Reubi, J.C; Maecke, H.R. Peptide-based probes for cancer imaging. J. Nucl. Med., 2008, 49(11), 1735-1738.
58. Zwanziger, D.; Beck-Sickinger, AG. Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr. Pharm. Des., 2008,14(24), 2385-2400.
59. Eberle, A.N.; Mild, G. Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods. J. Recept. Signal Transduct. Res., 2009, 29(1), 1-37.
60. Decristoforo, C.; Maina, T.; Nock, B.; Gabriel, M.; Cordopatis, P.; Moncayo, R. 99mTc-Demotate 1: first data in tumour patientsresults of a pilot/phase I study. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1211-1219.
61. Shah, T.; Kulakiene, I.; Quigley, A.M.; Warbey, V.S.; Srirajaskanthan, R.; Toumpanakis, C.; Hochhauser, D.; Buscombe, J.; Caplin, M.E. The role of 99mTc-depreotide in the management of neuroendocrine tumours. Nucl. Med. Commun., 2008, 29, 436-440.
62. Schweinsberg, C.; Maes, V.; Brans, L.; Bläuenstein, P.; Tourwé, DA.; Schubiger, P.A.; Schibli, R.; GarcíaGarayoa, E. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug. Chem., 2008, 19(12), 2432-2439.
63. Shi, J.; Jia, B.; Liu, Z.; Yang, Z.; Yu, Z.; Chen, K.; Chen, X.; Liu, S.; Wang, F. 99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug. Chem., 2008,19(6), 1170-1178.
64. Maes, V.; Brans, L.; Schweinsberg, C.; Garcia-Garayoa, E.; Bläuenstein, P.; Schubiger, PA.; Tourwé, D. Carbohydrated [99mTc(CO)3](NalphaHis)Ac-bombesin(7-14) analogs. Adv. Exp. Med. Biol., 2009, 611, 409-410.
65. Miao, Y.; Benwell, K.; Quinn, TP. 99mTcand 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J. Nucl. Med., 2007, 48(1),73-80.
66. Raposinho, PD.; Xavier, C.; Correia, JD.; Falcão, S.; Gomes, P.; Santos, I. Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties. J. Biol. Inorg. Chem., 2008, 13(3), 449-459.
67. Maes, V.; Garcia-Garayoa, E.; Bläuenstein, P.; Tourwé, D. Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J. Med. Chem., 2006, 49(5), 1833-1836.
68. Maina, T.; Nikolopoulou, A.; Stathopoulou, E.; Galanis, AS.; Cordopatis, P.; Nock, BA. [99mTc]Demotensin 5 and 6 in the NTS1R-targeted imaging of tumours: synthesis and preclinical results. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(11), 1804-1814.
69. Shi, J.; Wang, L.; Kim, YS.; Zhai, S.; Liu, Z.; Chen, X.; Liu, S. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J. Med. Chem., 2008, 51(24),7980-7990.
70. Haubner, R.; Decristoforo, C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front. Biosci., 2009, 14, 872-886.
71. Ananias, H.J.; de Jong, I.J.; Dierckx, R.A.; van de Wiele, C.; Helfrich, W.; Elsinga, P.H. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr. Pharm. Des., 2008, 14(28), 3033-3047.
72. von Guggenberg, E.; Sallegger, W.; Helbok, A.; Ocak, M.; King, R.; Mather, S.J.; Decristoforo, C. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J. Med. Chem., 2009, 52(15), 4786-4793.
73. Reubi, C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 781-793.
74. Mansi, R.; Tesauro, D.; Morelli, G.; Maecke, H.R. Multi-target peptide conjugates labeled with rhenium and technetium In: Technetium, rhenium and other metals in chemistry and Nuclear Medicine. SG, Editorial; Padova, 2006, Vol 7, pp. 305-308.
75. Deutsch, E.; Libson, K.; Vanderheyden, J.L.; Ketring, A.R.; Maxon, H.R. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int. J Rad. Appl. Instrum. B., 1986, 13, 465-477.
76. Volkert, W.A.; Goeckeler, W.F.; Ehrhardt, G.J.; Ketring, A.R. Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med., 1991, 32, 174-185.
77. Ehrhardt, G.J.; Ketring, A.R.; Turpin, T.A. In: Technetium and Rhenium in chemistry and Nuclear Medicine 3, Cortina International, Editorial; Verona, Italy. 1990, Vol. 3, pp. 631-631.
78. Boschi, A.; Duatti, A.; Uccelli, L. Development of technetium-99m and rhenium-188 radiopharmaceuticals containing a terminal metal-nitrido multiple bond for diagnosis and therapy. Top. Curr. Chem., 2005, 252, 85-115.
79. Rey, A.; Pirmettis, I.; Papadopoulos, M.; Giglio, J.; Leon, E.; Schreiber, F.; Paolino, A.; Fernandez, R.; Manta, E.; Chabalgoity, J.; Leon, A. Oxotechnetium and oxorhenium 3+1 mixed ligand complexes as potential melanoma targeting agents. World J. Nucl. Med., 2005, 4, 111-119.
80. Savio, E.; Gaudiano, J.; Robles, A.M.; Balter, H.; Paolino, A.; López, A.; Hermida, J.C.; De Marco, E.; Martinez, G.; Osinaga, E.; Knapp, Jr. F.F. Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl. Med., 2001, 1, 2.
81. Lam, M.G.; de Klerk, J.M.; van Rijk, P.P. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, S162-S170.
82. Lam, MG.; de Klerk, J.M.; van Rijk, P.P.; Zonnenberg, B.A. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med. Chem., 2007, 7(4),381-97.
83. Paes, F.M.; Serafini, A.N. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin. Nucl. Med., 2010, 40(2), 89-104.
84. Lattimer, J.C.; Corwin, L.A.; Stapleton, J.; Volkert, W.A.; Ehrhardt, G.J.; Ketring, A.R.; Anderson, S.K.; Simon, J.; Goeckeler, W.F. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium153-EDTMP. J. Nucl. Med., 1990, 31, 1316-1325.
85. Neves, M.; Gano, L.; Pereira, N.; Costa, M.C.; Costa, M.R.; Chandia, M.; Rosado, M.; Fausto, R. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nucl. Med. Biol., 2002, 29, 329-338.
86. Ando, A.; Ando, I.; Tonami, N.; Kinuya, S.; Kazuma, K.; Kataiwa, A.; Nakagawa, M.; Fujita, N. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl. Med. Commun., 1998, 19(6), 587-591.
87. Chakraborty, S.; Das, T.; Banerjee, S.; Balogh, L.; Chaudhari, P.R.; Sarma, H.D.; Polyák, A.; Máthé, D.; Venkatesh, M.; Janoki, G.; Pillai, M.R. 177Lu-EDTMP: A Viable Bone Pain Palliative in Skeletal Metastasis. Cancer Biother. Radiopharm., 2008, 23, 202-213.
88. Torres Martín de Rosales, R.; Finucane, C.; Mather, S.J.; Blower, P.J. Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases. Chem. Commun., 2009, 4847-4849.
89. Lambert, B.; Bacher, K.; Defreyne, L. Rhenium-188 based radiopharmaceuticals for treatment of liver tumours. Q. J. Nucl. Med. Mol. Imaging, 2009, 53(3), 305-310.
90. Boschi, A.; Uccelli, L.; Duatti, A.; Colamussi, P.; Cittanti, C.; Filice, A.; Rose, A.H.; Martindale, A.A.; Claringbold, P.G.; Kearney, D.; Galeotti, R.; Turner, J.H.; Giganti, M. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl. Med. Commun., 2004, 25(7), 691-699.
91. 188Re-labeled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl. Med. Commun., 2002, 23, 237-242.
92. Cyr, J.E.; Pearson, D.A.; Wilson, D.M.; Nelson, C.A.; Guaraldi, M.; Azure, M.T.; Lister-James, J.; Dinkelborg, L.M.; Dean, R.T. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J. Med. Chem., 2007, 50, 1354-1364.
93. 188Re-SOCTAtrastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl. Med. Biol., 2009, 36, 81-88.
94. Mutschler, J.; Steinbach, G.; Bunjes, D.; Reske, S.N.; Buchmann, I. Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha. Nuklearmedizin, 2009, 48, 30-36.
95. 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol. Ther., 2008, 7, 1116-1127.
96. Meares, C.F.; Moi, M.K.; Diril, H.; Kukis, D.L.; McCall, M.J.; Deshpande, S.V.; DeNardo, S.J.; Snook, D.; Epenetos, A.A. Macrocyclic chelates of radiometals for diagnosis and therapy. Br. J. Cancer, 1990, 62(10), 21-26.
97. Liu, S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Del. Rev., 2008, 60, 1347-1370.
98. Van Essen, M.; Krenning, E.P.; De Jong, M.; Valkema, R.; Kwekkeboom, D.J. Peptide Receptor Radionuclide Therapy with radiolabeled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol., 2007, 46, 723-734.
99. 177LuDOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother. Radiopharm., 2008, 23, 114-120.
100. Lucignani, G. Labeling peptides with PET radiometals: Vulcan's forge. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 209-215.
101. Froidevaux, S.; Calame-Christe, M.; Schuhmacher, J.; Tanner, H.; Saffrich, R.; Henze, M.; Eberle, A.N. A gallium-labeled DOTAalpha-melanocytestimulating hormone analog for PET imaging of melanoma metastases. J. Nucl. Med., 2004, 45, 116-123.
102. Zhang, H.; Schuhmacher, J.; Waser, B.; Wild, D.; Eisenhut, M.; Reubi, J.C.; Maecke, H.R. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1198-1208.
103. Pagou, M.; Zerizer, I.; Al-Nahhas, A. Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging? Hell. J. Nucl. Med., 2009, 12, 102-105.
104. Barnard, P.; Bayly, S.; Betts, H.; Bonnitcha, P.; Christlieb, M.; Dilworth, J.; Holland, J.; Pascu, S. Towards new copper based radiopharmaceuticals. Q. J. Nucl. Med. Mol. Imaging, 2008, 52, 174-184.
105. Bonnitcha, P.D.; V vere, A.L.; Lewis, J.S.; Dilworth, J.R. In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cucomplexes for the positron emission tomography imaging of hypoxia. J. Med. Chem., 2008, 51, 2985-2991.
106. DeNardo, S.J. Radioimmunodetection and therapy of breast cancer. Semin. Nucl. Med., 2005, 35,143-151.
107. Rossin, R.; Muro, S.; Welch, M.J.; Muzykantov, V.R.; Schuster, D.P. In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J. Nucl. Med., 2008, 49, 103-111.
108. Perk, L.R.; Visser, G.W.; Vosjan, M.J.; Stigter-van Walsum, M.; Tijink, B.M.; Leemans, C.R.; van Dongen, G.A. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med., 2005, 46, 1898-1906.
109. 177Lu. Bioconj. Chem., 2006, 17, 485-492.
110. Yoshinaga, K.; Chow, B.J.; Williams, K.; Chen, L.; deKemp, R.A.; Garrard, L.; Lok-Tin Szeto, A.; Aung, M.; Davies, R.A.; Ruddy, T.D.; Beanlands, R.S. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J. Am. Coll. Cardiol., 2006, 48, 1029-1039.